Cometriq
Term · Oncology and biomedicine · MLC-T-ONC-001932
A drug that contains the active ingredient cabozantinib-s-malate and is used to treat progressive medullary thyroid cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Cometriq blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cometriq is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.
| Identifier | MLC-T-ONC-001932 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-001932",
"term": "Cometriq",
"field": "Oncology and biomedicine",
"definition": "A drug that contains the active ingredient cabozantinib-s-malate and is used to treat progressive medullary thyroid cancer that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Cometriq blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cometriq is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.",
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/cometriq/"
}
Record 5,134 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.